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ABSTRACT 
 
BACKGROUND 
To assess adjunctive intravenous dexamethasone in adult community-acquired bacterial meningitis 
(BM) in daily practice.  
METHODS 
Analysis of consecutive patients (1990-2009) with acute community-acquired bacterial meningitis in a 
single centre in Zagreb, Croatia, N=304. Adjusted relative risks (RR, dexamethasone vs. no 
dexamethasone [control]) of Glasgow Outcome Scale (GOS)=1 (death) and GOS=5 (full recovery) at 
discharge/end of specific treatment were estimated considering demographics; co-morbidity; BM 
pathogenesis and on-admission characteristics and cerebrospinal fluid (CSF) inflammation markers; 
causative agent and antibiotic use.  
RESULTS 
240 (79%) patients had proven BM (43.1% S. pneumoniae, any other agent ≤ 8.2%). No independent 
effects of dexamethasone on GOS=1 or GOS=5 were observed in the entire cohort (dexamethasone 
n=119, control n=185; RR= 1.06, 95% CI 0.77-1.45 and RR=0.99, CI 0.83-1.20, respectively), 
microbiologically proven disease (dexamethasone n=104, control n=136; RR=0.97, CI 0.69-1.38 and 
RR=1.03, CI 0.82-1.28), pneumococcal disease (dexamethasone n=71, control n=60; RR=0.95, CI 
0.53-1.70 and RR=0.82, CI 0.57-1.18), and also in other BM, subgroups based on consciousness 
disturbance, CSF markers, prior use of antibiotics and timing of appropriate antibiotic treatment. CSF 
markers did not predict the outcomes.  
CONCLUSIONS 
Our experience does not substantiate the reported benefits of adjunctive dexamethasone in adult BM. 
Socio-economic and methodological factors do not seem to explain this discrepancy. Empirical use of 
dexamethasone in this setting appears controversial. 
 
KEY WORDS: adults; community-acquired bacterial meningitis; S. pneumoniae, dexamethasone  
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BACKGROUND 
Extensive experimental and animal data accumulated over the years strongly suggest that 
neuronal damage associated with poor outcomes in acute bacterial meningitis is largely mediated by a 
severe inflammatory host response triggered by bacterial invasion of the central nervous system. 
Bacterial toxins and cell lysis products, particularly in pneumococcal meningitis, augment the harmful 
effects on the brain through direct cytotoxicity and perpetuation of inflammation (1-4). These 
observations fuelled a therapeutic concept advocating the use of non-bacteriolytic antibiotics and 
suppression of inflammation (3,5). In this context, corticosteroids seemed to be a natural choice as an 
adjunctive anti-inflammatory treatment. However, clinical usefulness of corticosteroids in adult 
bacterial meningitis (BM) had long lacked sound empirical evidence (5). In 2002, a multicenter, 
randomized, placebo-controlled trial demonstrated the potential of an adjunctive intravenous 
dexamethasone regimen (10 mg immediately before or with the first parenteral antibiotic dose and 
every 6 hours thereafter, over 4 days) to reduce mortality and unfavourable outcomes in European 
adults with community-acquired BM, particularly those with pneumococcal disease (the most prevalent 
bacteriological form) (6). This particular schedule was recently reported to apparently improve the 
outcomes of pneumococcal diseases in daily practice in a developed European country (7). On the 
other hand, recent meta-analyses of placebo-controlled trails indicate that the effect of early 
dexamethasone in adults is seemingly less robust than theoretically expected, and might be affected 
by trial quality, socio-economic level of the country (reflecting on access to medical care, HIV infection 
prevalence and treatment possibilities, but probably also on other factors), causative agent and level 
of evidence of bacterial infection (5,8-10). Overall, the survival benefit is uncertain, although some 
benefit might be confined to the patients with pneumococcal meningitis in high-income countries (5,8-
10). The most consistent benefit seems to be the reduced risk of hearing loss, but this again does not 
seem to hold in the low-income countries and only a trend was observed in high quality trials (8,9). 
Interestingly, as indicated by both a recent meta-analysis of individual patient data from 5 trials and a 
recent Cochrane group meta-analysis (by the same authors) – the (lack of) dexamethasone effect was 
not affected by its commencement prior to (or with) the first antibiotic dose (as advocated in 
agreement with the “anti-inflammation” concept) vs. its commencement after antibiotic treatment had 
already begun (8,9). 
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Hence, although some patients in some societies (parts of the world) could benefit from adjunctive 
dexamethasone, its routine use in adult community-acquired BM is controversial (5,10). 
 Over the past 20 years we have been using adjunctive dexamethasone in treatment of adult 
community-acquired BM in line with the developments in the field. The primary objective of the present 
analysis of our patient database was to assess its effects on the disease outcome in daily practice. 
Secondary objective was to assess standard markers of subarachnoid inflammation determined on 
admission as outcome predictors. 
 
PATIENTS AND METHODS  
General design 
This is a retrospective analysis of consecutive adult (≥18 years of age) patients treated for acute 
community-acquired BM between January 1, 1990 and December 31, 2009 at the Zagreb Hospital for 
Infectious Diseases, a tertiary care university-affiliated teaching hospital with 320 beds. During this 
period, all patients suspected of having acute BM underwent the same standardized in-house protocol 
with a detailed prospective data recording. All patients were managed at the Department for 
neuroinfections and intensive care by adequately trained staff. For the purpose of the present 
analysis, the hospital electronic database and source data were searched independently by two 
investigators to identify qualifying patients and to double-check the extracted data. The analysis was 
approved by the institution’s Ethics Committee. 
Patients 
Bacterial meningitis was diagnosed based on clinical presentation (fever, headache, neck stiffness 
and disturbed consciousness with or without seizures and/or neurological deficits); supportive 
cerebrospinal fluid (CSF) findings (pleocytosis, increased protein concentration and decreased 
CSF/blood glucose ratio); and microbiological evidence: positive CSF culture or a negative CSF 
culture with a positive CSF polymerase chain reaction assay, positive blood culture, or a positive Gram 
stain of a CSF sample. Microbiologically not proven (probable) BM was diagnosed based on a 
compatible clinical picture and neutrophilic pleocytosis (≥1000 white cells/mL of CSF with >50% 
neutrophils) or CSF-blood glucose ratio < 0.4 and CSF protein concentration >45 mg/dL (11). 
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The disease was considered community-acquired if a patient had not been previously hospitalized, or 
if it occurred more than 2 weeks after a previous hospital discharge, or more than 4 weeks after a 
previous surgical treatment (11). 
Out of a total of 586 adults with BM treated during the observed period, the present analysis embraced 
304 patients. Exclusions were due to: nosocomial or shunt meningitis (n=184); missing or unclear data 
(based on agreement between the two investigators in charge of data extraction): on timing of 
antibiotic and/or dexamethasone commencement relative to disease occurrence, on relevant on-
admission assessment (e.g., consciousness level, laboratory findings) or assessment of the disease 
outcome (n=72); brain abscess or subdural empyema (n=18); meningitis limited to the spinal cord 
(n=8). 
Antibiotic treatment and treatment with dexamethasone 
Antibiotic treatment always followed the same scheme: initial empirical treatment recommended by the 
Hospital Drugs Committee was followed by, when applicable, a bacteriologically targeted treatment 
(adequate dose of a parenteral antibiotic that penetrates the blood-brain barrier and to which one or 
more of the isolated pathogens were sensitive). During the observed period, the recommended 
empirical therapy consisted of ceftriaxone or cefotaxime for subjects 18-50 years of age, and of 
parenteral ampicillin plus ceftriaxone in patients >50 years of age or in immunocompromised subjects 
and alcohol abusers. The majority of patients (189/304, 62.1%) received the initial empirical treatment 
with ceftriaxone or cefotaxime.  
The decision to introduce adjunctive dexamethasone in treatment of adult BM 20 years ago was 
based on the then existing reports of its favourable effects in pediatric Haemophilus influenzae type B 
meningitis (12,13). Dexamethasone was to be used in patients with clinical and CSF signs supporting 
the diagnosis of BM, except those with a recent history (within a month before admission for 
meningitis) of upper gastrointestinal bleeding or peptic ulcer. No other strict criteria were set, but the 
decision to use it in a particular patient was left at the attending physician’s discretion and clinical 
judgement. The lowest dose of intravenous dexamethasone was 4 x 8 mg/24 h and the highest dose 
was 4 x 12 mg/24 h, and dexamethasone was delivered over 48 (minimum) to 96 hours (maximum). 
The first dose was always delivered 15-20 minutes prior to or concomitantly with the first dose of 
parenteral antibiotic. The same routine was applied with other doses - whenever the antibiotic and 
dexamenthasone delivery schedules overlapped. 
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Outcomes 
We used the Glasgow Outcome Scale (GOS) score as a measure of disease outcome, as assessed at 
discharge/end of specific treatment for meningitis (7,14). GOS grades the outcomes as: death 
(GOS=1); vigil coma (GOS=2); conscious with severe neurological deficit (dependent) (GOS=3); 
moderate disability (independent, professionally incapable) (GOS=4) and independent, professionally 
capable, no or minor disability (GOS=5). Two (co)primary outcomes were defined: a) proportion of 
patients with GOS=1 (i.e., mortality); b) proportion of patients with GOS=5 (i.e., full recovery, as 
opposed to unfavourable outcomes: GOS <5). The interobserver agreement of GOS is high (7). 
Data analysis 
Data were summarized for the entire cohort and also separately for patients who received 
dexamethasone treatment and those who did not. Since the individual patient data were collected 
prospectively in a standardized manner and since the occurrence of both outcomes (GOS=1 and 
GOS=5) was relatively high (>10%), the analysis was based on determination of relative risks (RR) 
rather than odds ratios, using modified Poisson regression with robust error variance (15). 
The main analysis intended to detect potential associations between dexamethasone treatment 
(primary objective) and CSF indicators of inflammation (secondary objective) and either of the two 
primary outcomes within the entire cohort. Univariate analysis was performed using regression models 
with only one independent: dexamethasone (yes/no) or each of the three standard CSF inflammation 
indicators (CSF pleocytosis, protein concentration and CSF/blood glucose ratio). Additionally, cluster 
analysis (using least pth powers clustering criterion [p=1] to reduce the effect of outliers on cluster 
centres) demonstrated that the patients could be separated based on the three CSF parameters into 
two clusters: those with more and those with less pronounced “CSF inflammation”. The contrast 
between the two clusters was also estimated as a measure of the effect of “CSF inflammation” on the 
outcomes. The following further independent variables were considered in multivariate analysis: age; 
sex; time (days) elapsed since first symptoms (any) to admission; use of antibiotics (any) before the 
diagnosis of meningitis; presence of serious comorbidity [includes malignancy, immunodeficiency 
(immunosuppressants, human immunodeficiency virus infection or splenectomy), diabetes mellitus 
(DM), other endocrinological diseases, alcohol abuse and liver cirrhosis, other chronic organ diseases 
(lungs, heart, kidney, liver)]; presence of focal neurological symptoms on admission (includes aphasia, 
cranial nerve palsy, monoparesis or hemiparesis); leukocyte count on admission; pathophysiological 
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mechanism of the disease (e.g., meningitis following septicemia, or following middle ear infection or 
trauma; dichotomized as “following septicemia” and “other”); microbiologically verified BM (considered 
as yes/no, and also as pneumococcal/other bacterial/probable); worst Glasgow Coma Score (GCS) 
within 24 hours since admission as a continuous variable and also categorized into levels of 
consciousness disturbance as: none (GCS ≥15), mild (GCS 13-14), moderate (GCS 10-12 ) or severe 
(GCS ≤9); and timing of the appropriate antibiotic treatment (empirical as per in-house guidelines, or 
bacteriologically targeted, see above) commencement specifically in relation to the onset of 
consciousness disturbance and/or overt meningitis symptoms (e.g., fever, headache, vomiting, 
malaise)(16). Namely, although the “door-to-antibiotic” delay negatively affects the outcomes in 
community-acquired adult BM (particularly if > 2hours), timing of the appropriate antibiotic treatment 
relative to the onset of consciousness disturbance and/or other specific meningitis symptoms appears 
to be a particularly relevant predictor of the disease outcome (17,18). Therefore, considering that the 
database included anamnestic/heteroanamnestic data on disease course before hospital admission, 
appropriate antibiotic timing relative to the onset of meningitis symptoms was assessed as “within 24 
hours” or “later”, based on agreement between two investigators unaware of the patients outcome and 
dexamethasone treatment. Regarding the primary objective, multivariate models were built by entering 
“dexamethasone treatment” (default) and all other independents showing at least a trend of univariate 
association with the outcome (p<0.1), followed by consecutive removal of the independents with 
p>0.05 in the order of the highest p-value. If not already included, independents showing baseline 
imbalance between dexamethasone-treated and not treated patients were then forced into the model 
and were kept if model fit was significantly improved (based on the Chi2 test of the log-likelihood 
difference). The procedure was the same regarding the secondary objective, except that default 
variables were the three individual CSF markers of inflammation (individually and simultaneously) or 
alternatively, “more pronounced CSF inflammation” (vs. less) from the cluster analysis. 
Exploratory analysis intended to evaluate the effects of dexamethasone on disease outcomes in 
subgroups of patients based on: causative agent (pneumococcal/other bacterial/probable); appropriate 
antibiotic timing relative to the onset of meningitis symptoms (within 24 hours or not); antibiotic 
treatment prior to admission (i.e., prior to diagnosis and potential dexamethasone commencement); 
worst GCS score within the first 24 hours since admission (GCS <12 or ≥12) and severity of on-
admission CSF inflammation markers (the cluster with more pronounced vs. less pronounced 
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inflammation). Considering the rather small subgroup sizes, multivariate models were built based on 
information obtained from the main analysis. We used SAS 9.1.3 software (SAS Inc., Cary, NC). 
 
RESULTS 
Patient and disease characteristics 
Of the 304 patients, 119 (39.1%) were treated with dexamethasone. There were certain baseline 
imbalances between the dexamethasone-treated and not treated patients: the former slightly more 
frequently suffered from immunodeficiency, DM or malignancy; more frequently had the worst GCS 
score within the first 24 hours since admission <13; had somewhat more pronounced CSF pleocytosis, 
higher CSF protein concentration and lower CSF/blood glucose ratio and where, hence, more 
frequently categorized as having “more pronounced CSF inflammation” by the cluster analysis (Table 
1). Meningitis secondary to septicaemia was equally prevalent in the two subgroups, while minor 
imbalance existed regarding other pathophysiological mechanisms of the disease (Table 1). Also, 
dexamehtasone-treated patients somewhat more frequently had a microbiologically verified disease 
and particularly pneumococcal disease (with minor imbalance regarding other etiological agents) 
(Table 2). Timing of the adequate antibiotic treatment relative to the onset of typical meningitis 
symptoms (which also indicates the timing of dexamethasone commencement, where applicable) 
appeared similar in the two groups; however treatment commencement within 24 hours was slightly 
less frequent in the dexamethasone group (Table 2). Slightly more dexamethasone-treated than not 
treated patients died (GOS=1) and somewhat less fully recovered (GOS=5) (Table 2). 
Main analysis: effects of dexamethasone treatment and on-admission CSF inflammation 
markers on disease outcome 
No univariate association was observed between dexamethasone and mortality (incidence of GOS=1), 
whereas dexamethasone treatment appeared associated with a slightly reduced risk of full recovery 
(GOS=5) (Table 3), likely reflecting the mentioned imbalances in disease characteristics. Weak 
(statistically significant or borderline significant) univariate associations were observed between worse 
on-admission values of CSF inflammation markers and higher incidence of GOS=1 or lower incidence 
of GOS=5 (Table 3). The unadjusted risk of GOS=1 was clearly higher and the risk of GOS=5 was 
clearly lower in patients (n=86) categorized by the cluster analysis as having “more pronounced CSF 
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inflammation” (based on the above three markers) vs. those categorized as having “less pronounced 
CSF inflammation” (n=218) (Table 3). 
Multivariate models testing the effects of dexamethasone on mortality (GOS=1) or full recovery 
(GOS=5) included all adjustments relevant either because of their effect on the outcomes, or because 
of the imbalances between dexamethasone-treated and not treated patients (Table 4). No 
independent effect of dexamethasone on either outcome was observed (GOS=1, RR=1.06, 95% CI 
0.77-1.45; GOS=5, RR=0.99, 95% CI 0.83-1.20) (Table 4). 
 Multivariate models testing the effects of CSF inflammation markers on mortality (GOS=1) or full 
recovery (GOS=5) also accounted for relevant adjustments and no independent effect on either 
outcome was observed (Table 5).  
Exploratory analysis: effects of dexamethasone on disease outcome in patient subgroups 
Mortality appeared comparable for dexamethasone-treated and not treated patients in the subgroups 
of subjects with bacteriologically proven disease, pneumococcal disease or disease caused by other 
agents (Table 6). The rate of full recovery was somewhat lower in treated than not treated patients 
with pneumococcal disease (Table 6). Both outcomes appeared much better in not treated patients in 
the small subgroup of subjects with probable BM (Table 6). However, no consistent, statistically 
significant independent effect of dexamethasone on either mortality or full recovery was observed in 
any of these subgroups, or other patient subgroups based on starting consciousness disturbance 
(GCS <12 or GCS ≥12), timing of the appropriate antibiotic treatment relative to the onset of overt 
meningitis symptoms (≤24 hours or >24 hours), baseline level of CSF inflammation markers (more or 
less pronounced), or antibiotic use before admission/diagnosis verification (i.e., before, where 
applicable, dexamethasone commencement) (Table 7).  
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DISCUSSION 
 
The present analysis of our 20-year experience (January 1, 1990 – December 31, 2009) indicates no 
benefit of adjunctive intravenous (iv) dexamethasone in reducing mortality or increasing the likelihood 
of full recovery (GOS=5, in the literature commonly depicted as “favourable outcome”, as opposed to 
GOS<5) in adult community-acquired BM, pneumococcal or caused by other common agents, in daily 
practice (6,9). It also indicates no predictive value of the standard on-admission CSF markers of 
subarachnoid inflammation for these two outcomes. Considering the theoretical background 
emphasizing the need to suppress the inflammatory host response in order to improve the disease 
outcome, these two observations might be perceived as closely related (1-5).  
The presently observed lack of benefit of adjunctive iv dexamethasone is in contrast with the results of 
a double-blind placebo-controlled European trial (conducted between 1993 and 2001) that showed 
reduced mortality and increased full recovery (i.e., reduced “unfavourable outcome” defined as 
GOS<5) in adults with community-acquired BM (particularly pneumococcal) receiving a specific 
dexamethasone regimen: 10 mg iv 15-20 minutes before or with the first parenteral antibiotic dose, 
and every 6 hours thereafter, over 96 hours (6). It is also in contrast with the recent observational 
report from the Netherlands indicating that this regimen, when transferred to daily practice, might 
reduce mortality and increase the likelihood of full recovery from pneumococcal disease (7). Several 
points need to be considered in an attempt to identify the reasons for discrepancy between the 
present and reported results (6,7). 
 
Study design 
It is not the purpose of observational “real-life” data to question the existence of a treatment effect 
observed in a well-designed trial, rather it is to assess the transferability of the observed benefit into 
daily practice. Doing so through a retrospective analysis could be potentially burdened by susceptibility 
to bias. However, the standards of good clinical practice and the reflection of the real situation 
contribute somewhat to the strength of this study.  
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Socio-economic level of the country, patient characteristics and causative agents 
According to clinical trials, the benefits of adjunctive dexamethasone seen in high-income countries do 
not seem to hold in the low-income countries (5,9,10). Potential reasons for this discrepancy include 
reduced/delayed access to medical care (to an extent at which benefits of any intervention are 
reduced), overall low socio-economic standard (that may affect various aspects of medical care) and 
high prevalence of HIV infection with reduced possibility of its treatment in the low-income countries 
(5,10). The present data refer to a cohort of patients from Croatia, a central-eastern European 
transitional country. According to the 2009 World Bank data, regarding the gross domestic product and 
purchasing power parity per capita Croatia ranks 33rd out of 162 countries and the two indices are at 
the level of 40-80% of that in developed European Union member states (19). Urban population by far 
predominates and practically 100% of the population is embraced by a health insurance system that 
guarantees a completely free access to a wide network of primary, secondary and tertiary care 
institutions (20). Prevalence of HIV infection in Croatia is very low even in vulnerable populations. The 
cumulative prevalence for the period 1985-2005 is 553 patients, which is negligible for a country with a 
population of 4.4 million that has been stable at this level over the past 15-20 years (20,21). In this 
respect, Croatia is more similar to countries in which benefits of adjunctive dexamethasone are 
expected than to the “low-income countries” in which benefits are not expected (5,9,10). In line with 
this, the mortality (24% overall, 27.1% in pneumococcal disease) and full recovery rates (54% overall, 
49.6% in pneumococcal disease) in the current cohort (39.1% patients received adjunctive 
dexamethasone) (Table 2) greatly overlap with the observational Dutch data where mortality and full 
recovery rates in S. pneumoniae BM were 30% and 50%, respectively, in the 1998-2002 cohort (17% 
received adjunctive dexamethasone) or 20% and 61%, respectively, in the 2006-2009 cohort (92% 
received adjunctive dexamethasone)(7). Definitions of “adult” and “community-acquired” BM were 
practically identical in the present report as in the published European trial and observational data 
(6,7). Also, proportions of patients with malignancy, immunodeficiency (by the same criteria) or 
diabetes were similar in the present (18.4% overall, 26% in pneumococcal disease) and the published 
cohorts (23%) (7). In the current cohort, 52% of all patients and 70% of those with pneumococcal 
disease where admitted to the hospital within 30 hours since the onset of any (including mild, atypical) 
symptoms, which compares well with the reported 50% of patients admitted within the first 24 hours in 
the Dutch pneumococcal cohorts (7). Finally, as in the published reports, S. pneumoniae was the most 
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prevalent single causative agent in the current cohort, found in 43.1% of the overall patients and in 
55% of those with bacteriologically proven disease (6,7). This is in agreement with the European trial 
(36% and 46%, respectively) and observational data (62% and 69%, respectively) (6,7). Of notion, 
Neisseria meningitidis which was the causative agent in 1/3 of the patients in the European trial and 
for which the beneficial effect of dexamethasone was clearly lacking was found in only 6.3% of the 
current patients (7.9% of those with bacteriologically proven disease) (6). Because of the long 
observational period, some of the overall socio-economic factors probably have changed. 
Nevertheless, all relevant factors regarding the accessibility and the quality of medical care, as well as 
the prevalence of HIV infection remained very similar. Hence, it seems unlikely that the patient and 
causative agent characteristics could account for the discrepancy between the current and published 
results (6,7). 
 
Antibiotic treatment and dexamethasone regimen 
There is no substantial difference between antibiotic regimens applied in the current cohort 
(see Patients and methods) and those applied in the European trial and observational reports, which is 
understandable since they were developed based on the same common knowledge and 
developments in the field over the observed time (6,7). Also, considering the data on lag-times 
between (any) symptom onset and admissions (see above) and the fact that 66.8% of the current 
patients (67.2% of those with the pneumococcal disease) received appropriate treatment within 24 
hours since the onset of more specific symptoms, it seems unlikely that the observed discrepancy 
between the current and published results is generated by a discrepancy in the basic therapy (6,7).  
The European trial evaluated a specific dexamethasone regimen (4x10 mg/day over 4 days, started 
before or with the first antibiotic dose) and subjects who received antibiotics prior to assessment of 
eligibility were not enrolled (6). In the Dutch cohort of patients with pneumococcal disease and better 
outcomes (2006-2009), 77% of patients received this particular regimen and further 15% received 
dexamethasone with variations in dose, duration and commencement relative to commencement of 
antibiotics, whereas in the cohort with poorer outcomes (1998-2002), 3% received this particular 
regimen, and further 14% received variable dexamethasone treatments (7). Clearly, the current cohort 
differs regarding the dexamethasone treatment: the entire regimen varied from a (theoretical) 
minimum of 4x8 mg/day over 2 days to a maximum of 4x12 mg/day over 4 days, and 33.6% patients 
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had received some form of antibiotic treatment before hospital admission, verification of diagnosis and 
commencement of the appropriate antibiotic (and dexamethasone) treatment (exactly the same 
proportion of patients with “prior” antibiotic therapy was seen among patients not treated with 
dexamethasone). Hence, one cannot rule-out this disagreement as a potential source of discrepancy 
between the current and published results, although it does not seem likely that it could completely 
account for it (6,7). First, two recent meta-analyses of placebo-controlled trials demonstrated that 
commencing dexamethasone before (or with) the first antibiotic dose or after antibiotic treatment had 
already started had no impact on its effects (8,9). In the present analysis, dexamethasone had no 
effect on mortality or full recovery in the entire cohort, but also in the subgroup of patients who 
received antibiotics before dexamethasone, as well as in the subgroup in which dexamethasone was 
started immediately before or with the first antibiotic dose. Theoretically, the rationale of timing 
dexamethasone before (or with) the antibiotic seems reasonable, as it should suppress the potential 
pro-inflammatory effects of bacterial lysis. However, it does not seem likely that a few doses of e.g., 
oral antibiotic treatment (for example, at the early stage of the disease with no evident meningitis 
symptoms) would induce such damage that a consequent dexamethasone would be useless.  
Second, in the Dutch 2006-2009 cohort of patients with the pneumococcal meningitis, the rate of full 
recovery was 42% in patients who received no dexamethasone (8%), 64% in patients who received 
the exact 4-day regimen as in the European trial (77%), 53% in patients who received other 
dexamethasone treatment (different from that one) (15%) and 61% in patients who received any 
dexamethasone regimen (92%) (6,7). Therefore, even a regimen discrepant from the one proposed by 
the European trial resulted in an absolute risk increase of 11%, and “any dexamethasone regimen” (as 
opposed to no dexamethasone) resulted in an absolute risk increase of 19% (6). Therefore, “any” or 
even “erroneous” dexamethasone regimen would be expected to yield at least some benefit. In the 
current subgroup with pneumococcal disease, the rate of full recovery with “any dexamethasone” 
regimen was 42.3%, whereas it was 51.7% with no dexamethasone treatment. The unadjusted and 
adjusted relative risks were 0.82 (95% CI 0.57-1.18) and 1.12 (95% CI 0.83-1.50), respectively. 
Furthermore, in the current subgroup of patients who did not receive antibiotics prior to verification of 
diagnosis and commencement of appropriate antibiotic and, where applicable, dexamethasone, i.e., in 
patients where the disagreement between the current dexamethasone regimen and the one proposed 
by the European trial was confined to dose (4x8 mg/day to 4x12 mg/day vs. 4x10 mg/day) and 
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duration (2-4 days vs. 4 days) (n=94), the rate of full recovery with dexamethasone was 26/54 (48.2%) 
and with no dexamethasone treatment it was 21/40 (52.5%)(6). Therefore, even if, in a way, “stratified” 
in respect to dexamethasone treatment schedule, current results on dexamethasone effects are in 
discrepancy with the published ones and disagreements related to dexamethasone regimen cannot 
account (or, at least, cannot fully account) for it (7). 
Accounting for confounders 
The present analysis accounted for all relevant confounders known to affect mortality or fully 
recovery in adult community-acquired BM as suggested by the literature (e.g., age, severity of 
consciousness disturbance, presence of immunodeficiency, malignancy, diabetes mellitus and other 
serious comorbidity, S. pneumoniae as a causative agent) and as indicated by the imbalances in 
baseline characteristics of dexamethasone-treated and not treated patients (5-10). Naturally, 
adjustments can hardly compensate for randomization (in terms of having “patients comparably 
susceptible to treatment in the treatment and control groups”). In the current cohort, dexamethasone-
treated patients presented with, on average, somewhat more difficult disease (illustrating physicians’ 
tendency to introduce dexamethasone in more difficult patients), but the two groups largely overlapped 
in respect to all relevant diseases features. Under such circumstances, adjustments in multivariate 
models may greatly “straighten” the situation. For example, the crude rate of full recovery in the 
dexamethasone-treated patients was statistically significantly lower than in the non-treated patients, 
but multivariate analysis revealed that dexamethasone treatment is not harmful in this respect. 
Additionally, the present analysis adjusted for another effect that turned-out to be consistently very 
important regarding both analyzed outcomes: timing of appropriate antibiotic treatment relative to the 
onset of consciousness alteration or other overt meningitis symptoms. A delay in antibiotic treatment 
has a considerable unfavourable effect in adult BM and timing relative to the onset of more specific 
(and not “any”) meningitis symptoms seems to be particularly important (17,18,22). In the European 
trial, no adjustments were made for “timing of antibiotic treatment” and no data on this variable were 
provided (6).  One could assume that randomization ascertained a fair balance between the 
dexamethasone and placebo groups in this respect. But, this does not mean that adjusting for this 
variable could not have changed the estimate of the size of the dexamethasone effect (antibiotic 
timing not as a confounding, but as an ”effect-modifying” variable). 
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CONCLUSIONS 
Our 20-year experience in the treatment of adult community-acquired BM caused by S. 
pneumoniae or other common agents suggests no benefit of adjunctive iv dexamethasone treatment 
in terms of reduced mortality (GOS=1) and increased likelihood of full recovery (GOS=5). These 
observations are in discordance with the results of a randomized, placebo-controlled European trial 
and observational data (6,7). Potential methodological differences, socio-economic circumstances and 
patient characteristics do not seem to explain this discrepancy. Hence, although the specific 
dexamethasone regimen evaluated in the European trial might indeed be beneficial in some patients 
and is a part of the recommended treatment of adult BM, empirical use of adjunctive dexamethasone 
in this setting remains controversial (5,6,10,23).  
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TABLES 
Table 1.  Patient characteristics on admission and pathogenesis of meningitis, overall and for those   
                     treated (Dexa) and not treated (No dexa) with dexamethasone 
  All patients 
(N=304) 
 Dexa       
(n=119, 39.1%) 
 No dexa 
(n=185, 60.9%) 
Age (years)  50 (18-91)  49 (18-84)  50 (18-91) 
Men  187 (61.5)  72 (60.5)  115 (62.2) 
Immunodeficiency, DM or malignancya  56 (18.4)  25 (21.0)  31 (16.8) 
Other serious comorbidityb  86 (28.3)  33 (27.7)  53 (28.7) 
Any antibiotic prior to diagnosis  102 (33.6)  40 (33.6)  62 (33.5) 
Lag-time: any symptoms-admission (days)  2 (1-14)  2 (1-14)  3 (1-13) 
GCS (worst in 24 hours since admission)  10 (Q1,3 7.3-14)  9 (Q1,3 7-13)  12 (Q1,3 9-15) 
Consciousness disturbance (GCS-based)       
None (GCS=15)  74 (24.3)  20 (16.8)  54 (29.2) 
Mild (GCS=13-14)  75 (24.7)  22 (18.5)  53 (28.7) 
Moderate (GCS=10-12)  123 (40.5)  61 (51.3)  62 (33.5) 
Severe (GCS ≤ 9)  32 (10.5)  16 (13.5)  16 (8.7) 
Focal neurological deficitc   32 (10.5%)  15 (12.6)  17 (9.2) 
Leukocyte count (x 109/L)  15.7 (0.7-43.3)  17.6 (2.2-43.3)  15.1 (0.7-35.3) 
CSF WBC (x 103 cells/µL)   12.0 (0.05-300)  18.4 (0.1-206)  10.2 (0.05-300) 
CSF proteins (mg/dL)  311 (24-3400)  383 (24-2826)  251 (36-3400) 
CSF/blood glucose ratio (%)  17.4 (0-97.8)  7.5 (0-79.2)  21.5 (0-97.8) 
More pronounced CSF inflammationd  86 (28.3)  46 (38.7)  40 (21.6) 
Pathogenesis of meningitis       
Following septicaemia   92 (30.3)  36 (30.3)  56 (30.3) 
Following middle ear infection  78 (25.7)  37 (31.1)  41 (22.2) 
Following trauma  55 (18.0)  19 (16.0)  36 (19.5) 
Recurrent  3 (0.99)  1 (0.84)  2 (1.1) 
Other mechanisms  76 (25.0)  26 (21.9)  50 (27.0) 
Legend: 
DM – diabetes mellitus; GCS – Glasgow Coma Scale score; CSF – cerebrospinal fluid; WBC – white blood cells; 
Q1,3 – lower and upper quartile 
If not otherwise specified, data are median (range) or count (percent). 
a Includes: immunodeficiency due to immunosuppressants, HIV infection or splenectomy (3 patients overall), 
diabetes mellitus (29 patients overall [dexa 13/119, no dexa 16/185] and malignancy (25 patients overall [dexa 
11/119, no dexa 14/185]) 
b Includes: alcohol abuse or cirrhosis (48 patients overall [dexa 16/119, no dexa 32/185]), endocrinological 
disease except DM (6 patients overall) and chronic heart, lung, kidney or liver disease (37 patients overall [dexa 
18/119, no dexa 19/185]). Some patients suffered from more than one comorbidity (including malignancy, 
immunodeficiency and DM). 
c Includes one or more of the following: aphasia, cranial nerve palsy, monoparesis or hemiparesis 
d Cluster analysis classified patients into two subgroups (clusters), one with more pronounced indicators of CSF 
inflammation (n=86; median values: CSF WBC 25.6, CSF proteins 786 and CSF/blood glucose ratio 2.1%), and 
the other with less pronounced indicators of CSF inflammation (n=218; median values: CSF WBC 10.0; CSF 
proteins 221 and CSF/blood glucose ratio 26%). 
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Table 2.  Bacteriological disease characteristics, timing of adequatea antibiotic treatment and  
                  Glasgow Outcome Score at discharge/end of specific treatment of meningitis 
  All patients 
(N=304) 
 Dexa 
(n=119) 
 No dexa 
(n=185) 
Microbiologically verified bacterial  240 (79.0)  104 (87.4)  136 (73.5) 
CSF - culture (or PCR) positive  215 (70.7)  94 (79.0)  121 (65.4) 
CSF - Gram stain positive  172 (56.6)  77 (64.7)  95 (51.4) 
Blood culture positive  104 (34.2)  39 (32.8)  65 (35.1) 
Common etiological agents       
Streptococcus pneumoniae  131 (43.1)  71 (59.7)  60 (32.4) 
Listeria monocytogenes  25 (8.2)  6 (5.0)  19 (10.3) 
Neisseria meningitidis  19 (6.3)  11 (9.2)  8 (4.3) 
Other Streptococcus strains  11 (3.6)  1 (0.8)  10 (5.4) 
Staphylococcus aureus strains  10 (3.3)  3 (2.5)  7 (3.9) 
Other (mostly Gram-negative aerobes)  44 (14.5)  12 (10.1)  32 (17.3) 
Meningitis symptoms – adequate antibiotic (days)a  1 (0-10)  1 (0-10)  1 (1-8) 
Treatment started within 24 hoursa  203 (66.8)  74 (62.2)  129 (69.7) 
Glasgow Outcome Score (GOS)        
GOS 1 (death)  73 (24.0)  32 (26.9)  41 (22.2) 
GOS 2 (vigil comma)  4 (1.3)  3 (2.5)  1 (0.6) 
GOS 3 (severe deficits, dependent)  23 (7.6)  12 (10.1)  11 (6.0) 
GOS 4 (independent, professionally incapable)  41 (13.5)  17 (14.3)  24 (13.0) 
GOS 5 (independent, no/minor disability)  163 (53.6)  55 (46.2)  108 (58.4) 
 
Legend: 
CSF – cerebrospinal fluid; PCR – polymerase chain reaction 
Data are counts (percent) or median (range). 
aTiming of adequate antibiotic treatment relative to the onset of consciousness disturbance or other overt 
meningitis symptoms (e.g., fever, neck stiffness, headache, vomiting). Appropriate antibiotic: empirical as per in-
house guidelines (see Patients and Methods) or bacteriologically targeted (appropriate dose of a parenteral 
antibiotic that passes the blood-brain barrier and to which one or more isolated pathogens was sensitive). 
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Table 3.  Unadjusted effects of treatment with dexamethasone and on-admission cerebrospinal fluid 
(CSF) inflammation indicators on mortality (Glasgow Outcome Score [GOS]=1) and full recovery 
(GOS=5) in adult community-acquired acute bacterial meningitis (N=304). Relative risks (RR) are 
given with 95% confidence interval (CI). 
  GOS=1  GOS=5 
  RR (95% CI)  P  RR (95% CI)  P 
Dexamethasone treatment  1.21 (0.81-1.81)  0.344  0.79 (0.63-0.99)  0.046 
CSF WBC (104 cells/µL increase)  1.05 (1.02-1.08)  <0.001  0.96 (0.92-1.00)  0.066 
CSF proteins (100 mg/dL increase)  1.07 (1.05-1.08)  <0.001  0.90 (0.85-0.93)  <0.001 
CSF/blood glucose (10% decrease)  1.12 (1.00-1.25)  0.043  0.89 (0.86-0.93)  <0.001 
More pronounced CSF inflammationa   1.67 (1.12-2.48)  0.011  0.55 (0.40-0.75)  <0.001 
 
Legend: 
WBC – white blood cells 
a From cluster analysis, see Patients and methods and footnote to Table 1 for details. 
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Table 4.  Adjusted effects of dexamethasone treatment on mortality [Glasgow Outcome Score 
(GOS)=1] and full recovery (GOS=5) in adult community-acquired acute bacterial meningitis (N=304). 
Relative risks (RR) are given with 95% confidence interval (CI) 
  GOS=1a  GOS=5e 
  RR (95% CI)  P  RR (95% CI)  P 
Dexamethasone  1.06 (0.77-1.45)  0.724  0.99 (0.83-1.20)  0.999 
Age (by 10 years)  1.20 (1.05-1.37)  0.008  0.93 (0.88-0.98)  0.019 
GCSb (by 1 unit lower)  1.24 (1-18-1.31)  <0.001  0.90 (0.86-0.93)  <0.001 
Meningitis following septicaemia  1.53 (1.07-2.18)  0.019  0.79 (0.63-0.98)  0.032 
Pneumococcal meningitis  1.88 (1.37-2.59)  <0.001  ---  --- 
Immunodeficiencyc, malignancy or DM  1.55 (1.10-2.20)  0.013  ---  --- 
Meningitis symptoms – atb: ≤24 hoursd  0.48 (0.31-0.75)  0.001  2.63 (1.69-4.10)  <0.001 
Proven bacterial (any agent)  ---  ---  1.30 (1.08-1.56)  0.005 
Other serious comorbidity  ---  ---  0.74 (0.58-0.94)  0.014 
More pronounced CSF inflammation  ---  ---  0.80 (0.63-1.02)  0.071 
 
Legend: 
GCS – Glasgow Coma Score; DM – diabetes mellitus; Atb - antibiotic 
a Initial model included “dexamethasone” by default and variables showing at least possible univariate association 
(p<0.1) with the outcome. They were then removed consecutively if p>0.05. Removed variables: cerebrospinal 
fluid (CSF)/blood glucose ratio, CSF white blood cells count, CSF protein concentration (and, alternatively, “more 
pronounced CSF inflammation” from the cluster analysis, see footnote to Table 1), other serious comorbidity 
(besides immunodeficiency, malignancy or DM), microbiologically proven bacterial disease (vs. probable). When 
forced into the model, “more pronounced CSF inflammation” did not improve the model fit (p=0.530) and did not 
relevantly change the size or statistical significance of the dexamethasone effect. 
b Worst within the first 24 hours since admission 
c see footnote to Table 1 
d Timing of adequate antibiotic treatment, see footnote to Table 2 
e Model building followed the same procedure as for GOS=1. Almost identical variables were consecutively 
removed, except that “pneumococcal meningitis” was replaced by “proven, any agent” (there was no difference 
between pneumococcal disease and other proven agents) and “immunodeficiency, malignancy or DM” was 
replaced by “other serious comorbidity”. Also, when forced into the model, “more pronounced CSF inflammation” 
improved the model fit (p=0.040) and was included, although its p-value was >0.05. 
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Table 5.  Adjusted effects of on-admission cerebrospinal fluid (CSF) indicators of inflammationa on 
mortality [Glasgow Outcome Score (GOS)=1] and full recovery (GOS=5) in adult community-acquired 
acute bacterial meningitis (N=304). Relative risks (RR) are given with 95% confidence interval (CI) 
  GOS=1b  GOS=5b 
  RR (95% CI)  P  RR (95% CI)  P 
More pronounced CSF inflammation  0.84 (0.60-1.19)  0.326  0.81 (0.63-1.02)  0.078 
Age (by 10 years)  1.19 (1.04-1.37)  0.012  0.93 (0.88-0.98)  0.014 
GCSc (by 1 unit lower)  1.26 (1.19-1.33)  <0.001  0.90 (0.86-0.94)  <0.001 
Meningitis following septicaemia  1.49 (1.04-2.14)  0.028  0.78 (0.63-0.98)  0.030 
Pneumococcal meningitis  1.88 (1.37-2.60)  <0.001  ---  --- 
Immunodeficiencyd, malignancy or DM  1.52 (1.07-2.16)  0.019  ---   
Meningitis symptoms – atb: ≤24 hourse  0.47 (0.30-0.74)  0.001  2.55 (1.62-4.02)  <0.001 
Proven bacterial (any agent)  ---  ---  1.27 (1.06-1.52)  0.011 
Other serious comorbidity      0.74 (0.59-0.94)  0.014 
 
Legend: 
GCS – Glasgow Coma Score; DM – diabetes mellitus; Atb - antibiotic 
a No multivariate model indicated any adjusted effect of indicators of CSF inflammation (pleocytosis, protein 
concentration and CSF/blood glucose ratio, considered separately or simultaneously) on the outcomes. 
Presented models include “more pronounced CSF inflammation”, a binary variable obtained by cluster analysis of 
the three individual CSF indicators (see footnote to Table 1), which showed the most pronounced unadjusted 
effect (see Table 3) on the outcomes. 
b Multivariate model-building followed the same methodology as depicted in footnote to Table 4, except that “CSF 
inflammation” variables were default variables instead of “dexamethasone treatment”. As demonstrated, use of 
dexamethasone did not satisfy criteria to enter either model. 
c Worst within the first 24 hours since admission 
d see footnote to Table 1 
e Timing of adequate antibiotic treatment, see footnote to Table 2 
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Table 6.  Mortality (Glasgow Outcome Score [GOS]=1) and full recovery (GOS=5) in subgroups of 
adult patients with community-acquired bacterial meningitis in respect to causative agent 
  All patients  Dexamethasone   No dexamethasone 
  n  Count (%)  n  Count (%)  n  Count (%) 
Proven bacterial a  240    104    136   
GOS=1     65 (27.1)    27 (26.0)    38 (27.9) 
GOS=5     119 (49.6)    48 (46.2)    71 (52.2) 
S. pneumoniae  131    71    60   
GOS=1     34 (26.0)    18 (25.4)    16 (26.7) 
GOS=5     61 (46.6)    30 (42.3)    31 (51.7) 
Other agents a,b  109    33    76   
GOS=1     31 (28.4)    9 (27.3)    22 (29.0) 
GOS=5     58 (53.2)    18 (54.6)    40 (52.6) 
Probable bacterial a  64    15    49   
GOS=1     8 (12.5)    5 (33.3)    3 (6.1) 
GOS=5     44 (68.8)    7 (46.7)    37 (75.5) 
 
Legend: 
a see Patients and methods for microbiological diagnostic criteria 
b see Table 2 for the list of other identified agents 
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Table 7. Effects of dexamethasone treatment on mortality (Glasgow Outcome Score [GOS]=1) and full 
recovery (GOS=5) in subgroups of adult patients with community-acquired acute bacterial meningitis. 
Relative risks (RR) are given with 95% confidence interval (CI). 
  GOS=1  GOS=5 
Subgroup  RR (95% CI)  P  RR (95% CI)  P 
Proven bacterial (n=240)         
Dexamethasone – unadjusted effect  0.93 (0.61-1.42)  0.733  0.88 (0.68-1.15)  0.358 
Dexamethasone – adjusted effecta  0.97 (0.69-1.38)  0.877  1.03 (0.82-1.28)  0.827 
Pneumococcal meningitis (n=131)         
Dexamethasone – unadjusted effect  0.95 (0.53-1.70)  0.864  0.82 (0.57-1.18)  0.281 
Dexamethasone – adjusted effecta  0.80 (0.52-1.23)  0.303  1.12 (0.83-1.50)  0.456 
Other causative agents (n=109)         
Dexamethasone – unadjusted effect  0.94 (0.49-1.82)  0.860  1.04 (0.71-1.51)  0.853 
Dexamethasone – adjusted effecta  1.36 (0.81-2.26)  0.240  0.94 (0.70-1.26)  0.664 
Probable bacterial (n=64)         
Dexamethasone – unadjusted effect  5.44 (1.47-20.2)  0.011  0.62 (0.35-1.09)  0.095 
Dexamethasone – adjusted effecta  0.82 (0.53-1.26)  0.364  0.84 (0.56-1.27)  0.415 
Starting GCS <12 (n=153)b         
Dexamethasone – unadjusted effect  0.87 (0.60-1.24)  0.435  1.12 (0.66-1.89)  0.669 
Dexamethasone – adjusted effectc  1.11 (0.79-1.56)  0.544  0.99 (0.65-1.50)  0.947 
Starting GCS ≥12 (n=151)b         
Dexamethasone – unadjusted effect  1.18 (0.22-6.20)  0.847  0.91 (0.75-1.10)  0.324 
Dexamethasone – adjusted effectc  0.84 (0.23-3.00)  0.786  0.92 (0.77-1.10)  0.348 
Symptoms-Atb
 d ≤24 hours (n=203)         
Dexamethasone – unadjusted effect  1.58 (0.71-3.55)  0.264  0.85 (0.70-1.04)  0.110 
Dexamethasone – adjusted effecte  0.90 (0.44-1.85)  0.800  0.95 (0.79-1.14)  0.584 
Symptoms-Atb
 d >24 hours (n=101)         
Dexamethasone – unadjusted effect  0.91 (0.62-1.34)  0.643  0.87 (0.36-2.11)  0.759 
Dexamethasone – adjusted effecte  0.93 (0.67-1.31)  0.688  0.81 (0.38-1.74)  0.591 
Greater CSF inflammation (n=86)f         
Dexamethasone – unadjusted effect  0.93 (0.52-1.68)  0.815  1.23 (0.67-2.26)  0.500 
Dexamethasone – adjusted effectg  1.39 (0.87-2.23)  0.166  1.23 (0.77-1.98)  0.383 
 
Continues on the next page 
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Table 7. (continued) 
  GOS=1  GOS=5 
Subgroup  RR (95% CI)  P  RR (95% CI)  P 
Lesser CSF inflammation (n=218)f         
Dexamethasone – unadjusted effect  1.25 (0.73-2.14)  0.415  0.79 (0.61-1.01)  0.058 
Dexamethasone – adjusted effectg  0.84 (0.55-1.28)  0.419  0.93 (0.76-1.14)  0.503 
Atb before admission (dexa) (n=102)h         
Dexamethasone – unadjusted effect  1.55 (0.74-3.23)  0.243  0.64 (0.42-0.97)  0.037 
Dexamethasone – adjusted effectg  1.14 (0.61-2.10)  0.685  0.75 (0.54-1.03)  0.079 
No Atb before admission (dexa) (n=202)         
Dexamethasone – unadjusted effect  1.09 (0.67-1.76)  0.726  0.88 (0.67-1.16)  0.358 
Dexamethasone – adjusted effectg  0.93 (0.63-1.36)  0.701  1.11 (0.89-1.39)  0.349 
 
Legend: 
GCS – Glasgow Coma Scale; Atb – antibiotic; CSF – cerebrospinal fluid; dexa - dexamethasone 
a Adjustments for GOS=1: age, worst GCS score within 24 hours since admission, meningitis following 
septicaemia, immunodeficiency, malignancy or diabetes, appropriate antibiotic treatment within 24 since the onset 
of consciousness disturbance or other overt meningitis symptoms. Adjustment for GOS=5: the same, except 
immunodeficiency, malignancy or diabetes replaced by “other serious comorbidity”. 
b Worst GCS score within 24 hours since admission 
c Adjustments as in a, except that “starting GCS” replaced with “proven bacterial meningitis” 
d Timing of appropriate antibiotic treatment relative to the onset of overt meningitis symptoms (see footnote to 
Table 2 and Patients and Methods). 
e Adjustments as in a, but “antibiotic timing” replaced with “proven bacterial meningitis” 
f Clusters based on CSF markers of inflammation (see footnote to Table 1) 
g Adjustments as in a plus “proven bacterial meningitis” 
h Any antibiotic (oral, parenteral) before admission/verification of diagnosis and, when used, dexamethasone 
commencement 
